The Double Bind: Where America Needs GLP-1s Most but Can Afford Them Least

Sixteen states face what this index terms a “Double Bind”: they rank among the 20 states with the highest adult obesity prevalence (35% or above) while simultaneously ranking in the bottom half nationally for GLP-1 medication affordability. The average obesity rate across these 16 states is 37.6%, and the average worker must spend 13.5% of monthly take-home pay — equivalent to 17.5 hours of work — to afford one month of GLP-1 medication at the best available self-pay price of $349 per month.

The pattern is structural, not incidental. Double Bind states share a common economic profile: lower median hourly wages, lower household incomes, and lower personal savings rates. These same economic conditions that depress medication affordability are also associated with higher rates of food insecurity, limited access to preventive healthcare, and dietary patterns that contribute to obesity. The result is a self-reinforcing cycle: the states where GLP-1 medications could have the greatest public health impact are precisely the states where workers are least able to afford them. Of the 16 Double Bind states, 10 face the “160-Hour Wall” — where minimum-wage workers would need to work more than 160 hours (an entire full-time month) just to afford Wegovy at list price.

The Medicaid coverage gap compounds this crisis. Only 5 of the 16 Double Bind states have Medicaid programs that cover GLP-1 medications for obesity treatment, leaving workers in 11 states to pay entirely out of pocket when private insurance denies coverage. For a worker in Mississippi — the state ranked worst for affordability — a year of GLP-1 medication at the self-pay price consumes 149.7% of estimated annual personal savings. Until federal policy addresses both the pricing structure of GLP-1 medications and the patchwork of Medicaid coverage, the Double Bind will persist: the Americans who need weight loss medication most will remain the least able to afford it.